Astria Therapeutics at Jefferies Conference: Strategic Pipeline Insights

Astria Therapeutics (ATXS) presented at the Jefferies Global Healthcare Conference, highlighting its pipeline including Nevenibart for hereditary angioedema (HAE) and STAR310 for atopic dermatitis, with Phase III trial data for Nevenibart expected in early 2027 and Phase 1a data for STAR310 within 12-18 months. The company aims for Nevenibart to become a market leader in the projected $5.4 billion HAE market by 2030, and is targeting the 40% of atopic dermatitis patients unresponsive to current treatments with STAR310. With just under $300 million in cash, Astria's funding is expected to last until mid-2027, supporting key milestones.

Analysis

Astria Therapeutics (ATXS) presented a compelling strategic update at the Jefferies Global Healthcare Conference, emphasizing advancements in its key pipeline assets: Nevenibart for hereditary angioedema (HAE) and STAR310 for atopic dermatitis. Nevenibart, a monoclonal antibody inhibitor of plasmacallicrin, is currently in a pivotal Phase III trial, initiated in February 2025, with top-line data anticipated in early 2027. Proof-of-concept data showed a greater than 90% attack rate reduction, supporting potential Q3 and Q6 month dosing regimens, which could offer a significant advantage in convenience over existing HAE treatments. Astria aims for Nevenibart to achieve market leadership in the HAE market, projected to reach $5.4 billion by 2030. Long-term safety and efficacy data from the Alpha Solar extension trial for Nevenibart are expected by mid-2025. For STAR310, an OX40 antagonist for atopic dermatitis, Phase 1a data in healthy volunteers are expected within the next 12 to 18 months. This program targets the approximately 40% of patients unresponsive to current treatments and is designed to offer a differentiated safety profile by avoiding adverse effects like fever and chills associated with some competitor OX40 programs, potentially allowing for higher, more efficacious dosing. Financially, Astria reported a robust cash position of just under $300 million, expected to fund operations and key clinical milestones, including Nevenibart's Phase III data, until mid-2027.

Key Decisions for Investors

• Investors should closely monitor the upcoming mid-2025 Alpha Solar long-term extension data for Nevenibart and the STAR310 Phase 1a results expected within 12-18 months as key near-term catalysts that could significantly impact valuation.
• The company's strong cash runway through mid-2027 mitigates immediate financing concerns and supports the progression of Nevenibart towards potential market leadership in the substantial HAE market; its commercial strategy, including independent US launch and potential ex-US partnerships, warrants attention.
• Consider the potential of STAR310 to capture a significant share in the competitive atopic dermatitis landscape if upcoming Phase 1a data validate its differentiated safety and pharmacokinetic profile compared to other OX40 antagonists.